Rahul Naithani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rahul Naithani has a total of 239 co-authors. Here are the top co-authors by number of shared publications:
Nitin Dayal
Department of Lab Medicine Max Superspecialty Hospital Delhi India
24 shared publicationsM. Mahapatra
Department of Hematology, All India Institute of Medical Science, New Delhi, India
18 shared publicationsPronamee Borah
Department of Hematology and Bone Marrow Transplant, Gurugram, India
17 shared publicationsRajat Kumar
All India Institute of Medical Sciences
17 shared publicationsJagdish Chandra
Lady Hardinge Medical College and Kalawati Saran Children’s Hospital
11 shared publicationsNeerja Agrawal
Department of Hematology, All India Institute of Medical Sciences, New Delhi, India
11 shared publications
Latest Publications
- 14 July 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (7) , e329-e331
Extracorporeal Membrane Oxygenation for Pneumocystis jirovecii Pneumonia in a Child With Multisystem Langerhans Cell Histiocytosis
Background: Pneumocystis jirovecii pneumonia (PJP) is a rapidly progressive and potentially fatal opportunistic infection in non-HIV immunocompromised children. Mortality is particularly high when PJP progresses to acute respiratory distress syndrome (ARDS). The role of extracorporeal membrane oxygenation (ECMO) in this setting remains limited to select reports. Case Presentation: We report a 3-year-old boy with multisystem Langerhans cell histiocytosis receiving vinblastine and corticosteroids who developed severe PJP during consolidation therapy. Despite early initiation of high-dose trimethoprim-sulfamethoxazole, adjunctive corticosteroids, and escalation to invasive mechanical ventilation, he developed refractory hypoxemic and hypercapnic respiratory failure. Bronchoalveolar lavage multiplex polymerase chain reaction confirmed Pneumocystis jirovecii with concurrent Klebsiella pneumoniae . In the absence of hemodynamic compromise or multiorgan dysfunction, venovenous (V-V) ECMO was initiated as rescue support. Rapid improvement in gas exchange allowed decannulation on day 6 and extubation by day 8. Radiologic resolution occurred within 2 weeks. The child completed antimicrobial therapy, resumed maintenance chemotherapy, and remains well at 10-month follow-up on secondary PJP prophylaxis. Conclusion: This case underscores the importance of early recognition and aggressive supportive care. In selected patients with isolated, potentially reversible respiratory failure, timely initiation of V-V ECMO can be lifesaving and may facilitate recovery while definitive antimicrobial therapy takes effect.
- 14 July 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (7) , e329-e331
Extracorporeal Membrane Oxygenation for Pneumocystis jirovecii Pneumonia in a Child With Multisystem Langerhans Cell Histiocytosis
Background: Pneumocystis jirovecii pneumonia (PJP) is a rapidly progressive and potentially fatal opportunistic infection in non-HIV immunocompromised children. Mortality is particularly high when PJP progresses to acute respiratory distress syndrome (ARDS). The role of extracorporeal membrane oxygenation (ECMO) in this setting remains limited to select reports. Case Presentation: We report a 3-year-old boy with multisystem Langerhans cell histiocytosis receiving vinblastine and corticosteroids who developed severe PJP during consolidation therapy. Despite early initiation of high-dose trimethoprim-sulfamethoxazole, adjunctive corticosteroids, and escalation to invasive mechanical ventilation, he developed refractory hypoxemic and hypercapnic respiratory failure. Bronchoalveolar lavage multiplex polymerase chain reaction confirmed Pneumocystis jirovecii with concurrent Klebsiella pneumoniae . In the absence of hemodynamic compromise or multiorgan dysfunction, venovenous (V-V) ECMO was initiated as rescue support. Rapid improvement in gas exchange allowed decannulation on day 6 and extubation by day 8. Radiologic resolution occurred within 2 weeks. The child completed antimicrobial therapy, resumed maintenance chemotherapy, and remains well at 10-month follow-up on secondary PJP prophylaxis. Conclusion: This case underscores the importance of early recognition and aggressive supportive care. In selected patients with isolated, potentially reversible respiratory failure, timely initiation of V-V ECMO can be lifesaving and may facilitate recovery while definitive antimicrobial therapy takes effect.
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in Indian Journal of Cancer
- Vol. 63 (2) , 186-190
Second autologous hematopoietic stem cell transplantation in multiple myeloma
Background: High-dose melphalan followed by autologous stem cell transplantation (ASCT) is standard in multiple myeloma (MM), but relapse remains inevitable. Second ASCT2 is a salvage option for selected patients with durable remission after ASCT1. Reports from the Asia-Pacific region are limited. Methods: This retrospective study included six patients with relapsed MM who underwent ASCT2 between 2012 and 2025. Demographics, treatment characteristics, toxicity, engraftment, and outcomes were analyzed. All patients underwent fresh stem cell mobilization with granulocyte colony-stimulating factor and plerixafor without cryopreservation. Results: The median age at ASCT2 was 61 years (range, 47–65 years). The median interval between ASCT1 and ASCT2 was 66 months (range, 31–123 months). Two patients achieved partial remission (PR), 1 achieved very good partial remission (VGPR), and 3 achieved complete remission (CR) before ASCT2. Four patients received melphalan 140 mg/m² and 2 received melphalan 200 mg/m² for ASCT2. The median CD34⁺ cell dose infused during ASCT2 was 2.54 × 10⁶/kg (range, 1.42–21 × 10⁶/kg). Febrile neutropenia developed in 4 patients but was easily controlled with empiric antibiotics. Neutrophil recovery occurred at a median of 11 days (range, 10–14 days), and platelet recovery at 13 days (range, 12–15 days). Hospital stay duration ranged from 15 to 22 days, with a median of 18.5 days. There was no transplant-related mortality. The median follow-up of the study cohort was 28.5 months (range, 1–47 months). Two patients died at 35 and 47 months post-ASCT2, respectively, due to progressive disease. One patient was lost to follow-up after the second bone marrow transplant. Three patients remain alive and in sustained remission. Conclusion: ASCT2 is a feasible salvage strategy in selected Indian patients with MM, yielding favorable outcomes with acceptable toxicity.
- 1 April 2026
- Published by Wolters Kluwer Health in Indian Journal of Cancer
- Vol. 63 (2) , 186-190
Open AccessSecond autologous hematopoietic stem cell transplantation in multiple myeloma
Background: High-dose melphalan followed by autologous stem cell transplantation (ASCT) is standard in multiple myeloma (MM), but relapse remains inevitable. Second ASCT2 is a salvage option for selected patients with durable remission after ASCT1. Reports from the Asia-Pacific region are limited. Methods: This retrospective study included six patients with relapsed MM who underwent ASCT2 between 2012 and 2025. Demographics, treatment characteristics, toxicity, engraftment, and outcomes were analyzed. All patients underwent fresh stem cell mobilization with granulocyte colony-stimulating factor and plerixafor without cryopreservation. Results: The median age at ASCT2 was 61 years (range, 47–65 years). The median interval between ASCT1 and ASCT2 was 66 months (range, 31–123 months). Two patients achieved partial remission (PR), 1 achieved very good partial remission (VGPR), and 3 achieved complete remission (CR) before ASCT2. Four patients received melphalan 140 mg/m² and 2 received melphalan 200 mg/m² for ASCT2. The median CD34⁺ cell dose infused during ASCT2 was 2.54 × 10⁶/kg (range, 1.42–21 × 10⁶/kg). Febrile neutropenia developed in 4 patients but was easily controlled with empiric antibiotics. Neutrophil recovery occurred at a median of 11 days (range, 10–14 days), and platelet recovery at 13 days (range, 12–15 days). Hospital stay duration ranged from 15 to 22 days, with a median of 18.5 days. There was no transplant-related mortality. The median follow-up of the study cohort was 28.5 months (range, 1–47 months). Two patients died at 35 and 47 months post-ASCT2, respectively, due to progressive disease. One patient was lost to follow-up after the second bone marrow transplant. Three patients remain alive and in sustained remission. Conclusion: ASCT2 is a feasible salvage strategy in selected Indian patients with MM, yielding favorable outcomes with acceptable toxicity.
- 11 March 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- p. 1-4
Multiple Myeloma as a Second Primary Malignancy
- 11 March 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- p. 1-4
Multiple Myeloma as a Second Primary Malignancy
- Open Access
- 3 March 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (3) , 675-678
Big Bang to Blood Cells
- 3 March 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (3) , 675-678
Open AccessBig Bang to Blood Cells
- Open Access
- 1 January 2026
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 22 (1) , 178-180
Polatuzumab vedotin and obinutuzumab combination in octogenarians with B-cell non-Hodgkin lymphoma
The outcomes of elderly patients with lymphoma are poor. There is scarcity of data on outcomes of chemotherapy-free regimens in patients older than 80 years with a B-cell lymphoma. We report three octogenarians with B-cell NHL and the efficacy and safety of a nonchemotherapy regimen using a lower dose of polatuzumab vedotin and anti-CD20 monoclonal antibody. No infusion-related adverse events were noted. No patient developed neutropenia. Peripheral neuropathy was grade 2 in all cases. Recurrent UTI were a concern in two patients. After a median of 6 cycles (range 1–6) of polatuzumab therapy, all three patients had achieved CR. One patient was lost to follow-up and succumbed to a multidrug-resistant gram-negative UTI. One patient relapsed at 13 months and other is doing well in remission at 15 months.
- 1 January 2026
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 22 (1) , 178-180
Open AccessPolatuzumab vedotin and obinutuzumab combination in octogenarians with B-cell non-Hodgkin lymphoma
The outcomes of elderly patients with lymphoma are poor. There is scarcity of data on outcomes of chemotherapy-free regimens in patients older than 80 years with a B-cell lymphoma. We report three octogenarians with B-cell NHL and the efficacy and safety of a nonchemotherapy regimen using a lower dose of polatuzumab vedotin and anti-CD20 monoclonal antibody. No infusion-related adverse events were noted. No patient developed neutropenia. Peripheral neuropathy was grade 2 in all cases. Recurrent UTI were a concern in two patients. After a median of 6 cycles (range 1–6) of polatuzumab therapy, all three patients had achieved CR. One patient was lost to follow-up and succumbed to a multidrug-resistant gram-negative UTI. One patient relapsed at 13 months and other is doing well in remission at 15 months.
- Open Access
- 23 December 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (1) , 1-2
Charting the Future of Indian Journal of Hematology and Blood Transfusion: Metrics, Milestones, and the Path Ahead
- 23 December 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (1) , 1-2
Open AccessCharting the Future of Indian Journal of Hematology and Blood Transfusion: Metrics, Milestones, and the Path Ahead
- 23 July 2025
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 115, 102952
Refractory immune thrombocytopenia with Trex1 mutation positive probable monogenic lupus
- 23 July 2025
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 115, 102952
Refractory immune thrombocytopenia with Trex1 mutation positive probable monogenic lupus
- Open Access
- 11 April 2025
- Published by Springer Nature in Blood Research
- Vol. 60 (1) , 1-4
Very low-dose vemurafenib maintenance for cardiac Erdheim Chester disease
- 11 April 2025
- Published by Springer Nature in Blood Research
- Vol. 60 (1) , 1-4
Open AccessVery low-dose vemurafenib maintenance for cardiac Erdheim Chester disease
- 7 March 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (6) , e31654
A Novel Mutation in the Adenosine Deaminase‐2 Gene Presenting as Severe Chronic Neutropenia With Myeloid Hypoplasia
- 7 March 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (6) , e31654
A Novel Mutation in the Adenosine Deaminase‐2 Gene Presenting as Severe Chronic Neutropenia With Myeloid Hypoplasia
- 27 January 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (4) , 1-4
Prevalence of Anemia of Chronic Disease/Inflammation at a Tertiary Care Hospital in North India
There is a lack of data from India on the prevalence of anemia of chronic disease or inflammation. This was a prospective observational cross-sectional pre
- 27 January 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (4) , 1-4
Prevalence of Anemia of Chronic Disease/Inflammation at a Tertiary Care Hospital in North India
There is a lack of data from India on the prevalence of anemia of chronic disease or inflammation. This was a prospective observational cross-sectional pre